New drugs promise to change the therapeutic landscape of breast cancer. First results from a phase III clinical trial of the combination drug, T-DM1, show that it significantly improves the length of time before the disease worsens in women with advanced HER2 positive breast cancer whose cancer has recurred or progressed despite previous treatments, including trastuzumab and lapatinib. In a late-breaking presentation to the 2013 European Cancer Congress ...
via Medindia Health News More READ
No comments:
Post a Comment